We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M Turnover 22.92%
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+35.19%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$336M
AUM Growth
+$28.4M
Cap. Flow
-$47.2M
Cap. Flow %
-14.05%
Top 10 Hldgs %
56.86%
Holding
90
New
10
Increased
16
Reduced
26
Closed
16
Avg Time Held
2.2 years
Top 10 Avg Time Held
1.1 years
Top 20 Avg Time Held
1.9 years

Top Buys

Rank Stock Value
1
LKFT icon
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$4.4M
2
FLNA icon
Filana Therapeutics
FLNA
+$4.02M
3
VERO icon
Venus Concept
VERO
+$3.39M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$2.94M
5
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$2.73M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$22.2M
2
ARCT icon
Arcturus Therapeutics
ARCT
+$9.85M
3
FATE icon
Fate Therapeutics
FATE
+$6.46M
4
BEAT icon
BioTelemetry, Inc.
BEAT
+$2.89M
5
BPMC icon
Blueprint Medicines
BPMC
+$2.76M

Sector Composition

Rank Sector Weight
1 Healthcare 96.39%
2 Miscellaneous 3.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
STXS icon
1
Stereotaxis
STXS
$104M
$69.6M 20.72%
13,680,554
– –
2013 Q2
30 quarters
FATE icon
2
Fate Therapeutics
FATE
$230M
$30.4M 9.05%
334,360
-104,100
-24% -$6.46M
2019 Q2
6 quarters
BPMC icon
3
DELISTED
Blueprint Medicines
BPMC
$23.2M 6.9%
206,911
-26,178
-11% -$2.76M
2016 Q4
16 quarters
SAGE icon
4
DELISTED
Sage Therapeutics
SAGE
$15.7M 4.67%
181,306
+23,000
+15% +$1.7M
2017 Q4
12 quarters
DRNA
5
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$12.9M 3.85%
587,756
+133,520
+29% +$2.94M
2018 Q2
10 quarters
NBIX icon
6
Neurocrine Biosciences
NBIX
$13.9B
$8.84M 2.63%
92,208
+2,000
+2% +$193K
2016 Q1
19 quarters
LKFT icon
7
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.96B
$7.96M 2.37%
80,375
+36,000
+81% +$4.4M
2015 Q3
21 quarters
DXCM icon
8
DexCom
DXCM
$33B
$7.82M 2.33%
84,552
– –
2017 Q3
13 quarters
ATRC icon
9
AtriCure
ATRC
$2.93B
$7.42M 2.21%
133,229
– –
2013 Q2
30 quarters
IBB icon
10
iShares Biotechnology ETF
IBB
$10.7B
$7.18M 2.14%
47,400
-8,500
-15% -$1.21M
2016 Q4
16 quarters
BHVN icon
11
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$7.04M 2.09%
82,100
-2,500
-3% -$212K
2018 Q2
10 quarters
CSII
12
DELISTED
Cardiovascular Systems, Inc.
CSII
$6.62M 1.97%
151,200
– –
2018 Q2
10 quarters
ARNA
13
DELISTED
Arena Pharmaceuticals Inc
ARNA
$5.9M 1.76%
76,815
+1,000
+1% +$75K
2018 Q1
11 quarters
XENE icon
14
Xenon Pharmaceuticals
XENE
$3.36B
$5.33M 1.59%
346,535
– –
2015 Q3
21 quarters
PRQR icon
15
ProQR Therapeutics
PRQR
$206M
$5.2M 1.55%
1,237,400
– –
2017 Q4
12 quarters
AFMD icon
16
DELISTED
Affimed
AFMD
$5.09M 1.51%
87,436
-4,992
-5% -$235K
2019 Q4
4 quarters
STIM icon
17
Neuronetics
STIM
$149M
$4.93M 1.47%
443,717
-52,055
-10% -$391K
2019 Q3
5 quarters
IDYA icon
18
IDEAYA Biosciences
IDYA
$3.26B
$4.64M 1.38%
331,661
– –
2020 Q3
1 quarter
TBIO icon
19
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$4.15M 1.24%
225,393
+34,463
+18% +$617K
2020 Q3
1 quarter
ARAY icon
20
Accuray
ARAY
$19.9M
$4.06M 1.21%
974,400
-99,900
-9% -$367K
2019 Q2
6 quarters
TVRD icon
21
Tvardi Therapeutics
TVRD
$14.1M
$3.96M 1.18%
7,262
+390
+6% +$204K
2017 Q3
13 quarters
AERI
22
DELISTED
Aerie Pharmaceuticals
AERI
$3.9M 1.16%
288,440
+4,000
+1% +$48.3K
2014 Q3
25 quarters
ASND icon
23
Ascendis Pharma A/S
ASND
$14.9B
$3.88M 1.15%
23,237
-6,000
-21% -$992K
2015 Q1
23 quarters
AGTC
24
DELISTED
Applied Genetic Technologies Corporation
AGTC
$3.69M 1.1%
903,429
-191,710
-18% -$942K
2015 Q1
23 quarters
LMNX
25
DELISTED
Luminex Corp
LMNX
$3.56M 1.06%
154,091
– –
2017 Q3
13 quarters
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, DAFNA Capital Management held 90 positions worth $336M, up 9.2% from $308M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

DAFNA Capital Management withdrew a net $47.2M in Q4 2020, closing 16 positions and reducing 26 holdings. Its most notable exit was Immunomedics Inc, an estimated $22.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Miscellaneous.

Against the trend, DAFNA Capital Management opened a new position in Filana Therapeutics worth $3.07M.

  • DAFNA Capital Management's largest Q4 2020 buy was Filana Therapeutics: 450,000 shares worth $3.07M.
  • DAFNA Capital Management added most to Lakefront Biotherapeutics American Depositary Shares in Q4 2020, an estimated $4.4M increase.
  • DAFNA Capital Management's biggest Q4 2020 reduction was Fate Therapeutics, cutting an estimated $6.46M.
  • DAFNA Capital Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $22.2M.
  • DAFNA Capital Management's ten largest holdings make up 57% of its $336M portfolio in Q4 2020.
  • DAFNA Capital Management opened 10 new positions and closed 16 in Q4 2020.
  • DAFNA Capital Management's portfolio value rose 9.2% quarter-over-quarter to $336M.

Based on DAFNA Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.